Redwood Pharma to present at Aktiespararnas Småbolagsdagen, June 11, 2018

Redwood Pharma will be presenting at Aktiespararnas Småbolagsdagen at the Sheraton Hotel in Stockholm, one of Scandinavia's leading investor forums on June 11 at 10:00 a.m. This presentation will be streamed live over the internet.

To register for the event being held at the Sheraton Hotel in Stockholm at 10:00, please visit and fill in the requisite form. A link to the event can be found on this site as well.

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ)
Tel: +46 (0) 70 232 29 29

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).

For more information visit:


Om oss

Redwood Pharma ska utveckla nya ögonläkemedel inom områden där det finns stora medicinska behov och god marknadspotential. Kompetensen inom Bolaget ligger främst inom formulering och tidig klinisk utveckling, varför licensavtal därefter ska ingås med större läkemedelsbolag. Licenspartnern ska i sin tur slutföra de kliniska försöken, registrera produkterna och därefter marknadsföra och sälja produkterna. Redwood Pharma ska få sina intäkter från multipla licensavtal med större läkemedelsbolag.


Dokument & länkar